TP53 and head and neck squamous cell carcinoma: More than 70% of reported HNSCC cases have an inactivating mutation in TP53, most of which are hotspot mutations.31 As a demonstration of principle, we proceeded to test extracts from frozen primary HNSCC biopsies from two patients, by means of a blinded experiment, without prior knowledge of the mutational status of codon p.R273.